Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Fineline Cube Dec 31, 2025
Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Fineline Cube Dec 31, 2025
Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Fineline Cube Dec 31, 2025
Company Deals

Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline

Fineline Cube Dec 31, 2025
Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Fineline Cube Dec 30, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Fineline Cube Dec 31, 2025
Company Drug

Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy

Fineline Cube Dec 31, 2025
Company Drug

Luzhu Biotechnology’s Herpes Zoster Vaccine LZ901 Concludes Phase II Study

Fineline Cube May 31, 2023

Beijing Luzhu Biotechnology Co., Ltd (HKG: 2480), a leading maker of human vaccines and therapeutic...

Company Drug

CMS Receives NMPA Approval for Tildrakizumab for Plaque Psoriasis Treatment

Fineline Cube May 31, 2023

China Medical System Holdings (CMS; HKG: 0867) has announced receiving marketing approval from the National...

Company Deals

Cutia Therapeutics Lists on HKEX with HKD527 Million IPO for Dermatology Therapies

Fineline Cube May 31, 2023

Dermatology therapy developer Cutia Therapeutics (HKG: 2487) has successfully made its initial public offering (IPO),...

Company Drug

CSPC Pharmaceutical’s AlaMab Therapeutics Presents Positive ALMB-0168 Data at ASCO

Fineline Cube May 31, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its subsidiary, AlaMab Therapeutics Inc.,...

Company Deals Drug

Betta Pharmaceuticals Secures Exclusive Rights to C4 Therapeutics’ CFT8919 in Greater China

Fineline Cube May 31, 2023

China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced an exclusive licensing agreement with US...

Company Deals

Lynk Pharmaceuticals Secures RMB 200 Million in Series C1 Financing Round

Fineline Cube May 31, 2023

China-based Lynk Pharmaceuticals Co., Ltd has successfully raised RMB 200 million (USD 28.3 million) through...

Policy / Regulatory

Digital China Development Report Highlights Growth of Digital Healthcare Ecosystem

Fineline Cube May 31, 2023

The Cyberspace Administration of China (CAC) has released the Digital China Development Report (2022), providing...

Company Drug

BeiGene’s Brukinsa Receives Canadian Approval for Chronic Lymphocytic Leukemia

Fineline Cube May 31, 2023

China-based BeiGene Ltd (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced that its Bruton’s tyrosine...

Company

Sanofi’s Commitment to China: Expansion, Digital Innovation, and Local R&D

Fineline Cube May 31, 2023

Wayne Shi, president of France-based Sanofi’s (NASDAQ: SNY) Greater China business, has been discussing the...

Company Deals

XtalPi Partners with Eli Lilly for AI-Driven Drug Discovery Services

Fineline Cube May 31, 2023

Sino-US artificial intelligence (AI) firm XtalPi Inc. has been enlisted by US-giant Eli Lilly &...

Company Drug

Chia Tai Tianqing’s Biosimilar Rituximab Approved by China’s NMPA for Lymphoma Treatments

Fineline Cube May 31, 2023

China-based Chia Tai Tianqing has announced receiving a market approval from the National Medical Products...

Company Drug

Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for SHR-2106 and HRS-1893 Clinical Trials

Fineline Cube May 31, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has separately announced receiving clinical trial approvals...

Company Deals

Galvanize Therapeutics Partners with Energenx Medical for Greater China Expansion

Fineline Cube May 31, 2023

US-based Galvanize Therapeutics Inc. has revealed a licensing deal with Shanghai-based Energenx Medical Ltd, which...

Company Drug

AstraZeneca Launches Calquence in China for Mantle Cell Lymphoma Treatment

Fineline Cube May 30, 2023

UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has announced the official market launch of Calquence...

Company Deals

Kangtai Biological Partners with Indian Pharmaceutical Giant for 13-Valent Pneumonia Vaccine

Fineline Cube May 30, 2023

Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a leading Chinese biopharmaceutical company, has entered...

Company Deals

Medtronic Launches AiBLE Orthopedic Ecosystem and Partners with Allinmd Orthopedics in China

Fineline Cube May 30, 2023

US-based Medtronic Inc., (NYSE: MDT) has launched AiBLE, an innovative ecological ecosystem concept for orthopedics,...

Company Deals

TYK Medicines Partners with WuXi STA for Comprehensive CMC Services

Fineline Cube May 30, 2023

Shanghai-based TYK Medicines has announced a partnership with WuXi STA, a subsidiary of WuXi AppTec...

Company Deals

Beijing’s E-Health Now Secures Tens of Millions in Series B Financing

Fineline Cube May 30, 2023

E-Health Now, a comprehensive health management platform headquartered in Beijing, has reportedly raised tens of...

Company Deals

Boyi Biotech Secures Over RMB100 Million in Series A Financing Led by JOLMO

Fineline Cube May 30, 2023

Boyi Biotech, a prominent biological microspheres developer headquartered in Changzhou, has reportedly secured more than...

Company Deals

Mindray Partners with Vazyme Biotech to Develop Automated Infection Screening Solutions

Fineline Cube May 30, 2023

China-based medical device company Mindray (SHE: 300760) has entered into a partnership with fellow Chinese...

Posts pagination

1 … 457 458 459 … 603

Recent updates

  • Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal
  • HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review
  • NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion
  • Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China
  • Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.